Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

By sjmartinez • October 17, 2022

Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Borg C, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Collins H, Mitra S, Yang Y, Catenacci DVT, Lee KW. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022 Oct 13:S1470-2045(22)00603-9. doi: 10.1016/S1470-2045(22)00603-9. Epub ahead of print. PMID: 36244398.

Tags: Digestive Diseases, Hematology/Oncology, Publications

Integrating Natural Language Processing With ChatGPT to Improve Quality of Artificial Intelligence Summaries of Prostate Cancer Consultations

Friedrich NA, Das SK, Luu M, Daniels JP, Heard J, Barsegyan A, Freedland SJ, Spiegel B, Kokorowski PK, Gonzalez Hernandez G, Daskivich TJ. Integrating Natural[...]

Frontier AI companies as biotech acquirers

Palermo A. Frontier AI companies as biotech acquirers. Nat Biotechnol. 2026 Jul 7. doi: 10.1038/s41587-026-03214-0. Epub ahead of print. PMID: 42414651.

Prevalence and Impact of Protein-Calorie Malnutrition in Hospitalized Patients with Steatotic Liver Disease

Alexandra CG, Sowon K, Andrew R, Peng-Sheng T, Berkeley NL, Po-Hung C. Prevalence and Impact of Protein-Calorie Malnutrition in Hospitalized Patients with Steatotic Liver Disease.[...]